Granules India Limited has completed the full acquisition of Senn Chemicals AG, a Swiss company specialising in peptide development and manufacturing. This move is part of Granules’ plan to grow in the field of science and innovation, especially in peptide-based medicines. 

Benefits and Future Plans

This acquisition will strengthen Granules’ capabilities in the peptide therapeutics sector and CDMO (Contract Development and Manufacturing Organisation) services. It will help the company develop new drugs like GLP-1 receptor agonists used for treating diabetes and obesity. Both companies have already started working together on product development, with plans for a wider range of peptide-based drugs.

Statement from Executive 

Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, stated, “The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organisation. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialised CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments. Senn’s specialised expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space.”

About Granules India

Granules India started in 1991 and, based in Hyderabad, is a fast-growing pharmaceutical company. It handles the full manufacturing process from raw ingredients to finished medicines and serves over 300 customers in more than 80 countries. The company runs 10 factories (8 in India and 2 in the USA) and has approvals from major global health authorities.

Granules India Share Price Performance 

As of April 11, 2025, at 11:00 AM, Granules India Limited Share Price is trading at ₹450.35 per share, reflecting a profit of 4.47% from the previous closing price. Over the past month, the stock has registered a loss of 5.92%. The stock’s 52-week high stands at ₹721.00 per share, while its low is ₹389.35 per share.

About Senn Chemicals

Senn Chemicals, established in 1963 and based in Switzerland, is well-known for making custom peptides. They support companies in the pharmaceutical, cosmetic and theragnostic fields. They use advanced methods like Liquid-Phase and Solid-Phase Peptide Synthesis and provide services from research to full-scale production.

Conclusion

The deal helps Granules grow in advanced drug development and expand globally. It marks a big step in its journey toward offering next-generation treatments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Torrent Power Limited announced that its wholly owned subsidiary, Torrent Green Energy Pvt. Ltd. (TGEPL), has established a new company named Torrent Urja Projects Pvt. Ltd. (TUPPL). 

Ownership and Financial Details

• Ownership: TUPPL is fully owned by TGEPL, which is itself a wholly owned subsidiary of Torrent Power Limited.
• Capital: Both the authorised and paid-up capital of TUPPL is ₹5,00,000.
• Turnover: Currently, TUPPL has no turnover as it hasn’t started operations yet.
• Acquisition Type: This was a cash investment involving the purchase of 50,000 shares at ₹10 each.

Purpose and Business Activities

TUPPL has been formed to take on infrastructure development projects related to various energy sources like solar, wind, hydro, thermal, nuclear, green hydrogen, coal, gas and more. It will offer services like:

• Engineering and project consultancy
• Construction and installation of power facilities
• Trading and supply of equipment and materials
• Managing and operating power plants

Background of the New Entity

Torrent Urja Projects Pvt. Ltd. is a newly incorporated company registered in Ahmedabad, Gujarat, on April 9, 2025. It hasn’t started any business activity yet and is entirely based in India.

Share Price Performance 

As of April 11, 2025, at 10:20 AM, Torrent Power Share Price is trading at ₹1,532.70 per share, reflecting a profit of 0.12% from the previous closing price. Over the past month, the stock has registered a profit of 14.86%. The stock’s 52-week high stands at ₹2,037.00 per share, while its low is ₹1,207.25 per share.

Conclusion

The incorporation of TUPPL reflects Torrent Power’s commitment to growth in the clean energy sector. By expanding its operational capabilities through this new subsidiary, the company is well-positioned to take on large-scale infrastructure and renewable energy projects both in India and abroad.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Sun Pharmaceutical Industries Limited has achieved a critical legal victory in its ongoing battle concerning the launch of its product, LEQSELVI (deuruxolitinib), in the United States. 

This comes following a ruling from the U.S. Court of Appeals for the Federal Circuit, which lifted a previously imposed preliminary injunction. The decision removes legal barriers that had delayed the company’s product rollout. While the primary litigation with Incyte Corporation is yet to be resolved, this interim judgment marks a turning point for the pharmaceutical giant.

Court Ruling Favouring Sun Pharma

On April 9, 2025, an oral argument was presented before the U.S. Court of Appeals for the Federal Circuit regarding Sun Pharma’s appeal against the District Court of New Jersey’s earlier decision. That decision had enforced a preliminary injunction that prevented the company from launching LEQSELVI  in the U.S. market. 

However, following the hearing, the Federal Circuit issued a favourable ruling, vacating the injunction with immediate effect. This legal development now enables Sun Pharma to proceed with its commercial plans for LEQSELVI, free from judicial restrictions.

The preliminary injunction was a significant obstacle, initially brought about by litigation initiated by Incyte Corporation. With the court now vacating the order, Sun Pharma is legally positioned to prepare for the launch of its product in the competitive U.S. pharmaceutical landscape.

Next Steps and Strategic Implications

Although the preliminary injunction is no longer in effect, Sun Pharma has indicated that the broader legal proceedings with Incyte Corporation are still in progress. The company has reassured stakeholders that it will announce its launch strategy for LEQSELVI in due course.

This development underscores the importance of navigating regulatory and legal frameworks efficiently, especially in highly competitive sectors such as biopharmaceuticals. Sun Pharma’s ability to clear this hurdle not only demonstrates its legal preparedness but also signals confidence in its pipeline and product portfolio.

Sun Pharma Share Performance 

As of April 11, 2025, at 11:30 AM, Sun Pharma Share Price is trading at ₹1,690.60 per share, reflecting a profit of 2.32% from the previous closing price. Over the past month, the stock has registered a surge of 2.13%.

Conclusion

The U.S. Court of Appeals’ decision to lift the injunction marks a significant milestone for Sun Pharmaceutical Industries. While the legal dispute with Incyte Corporation is not yet concluded, this ruling allows Sun Pharma to move forward with launching LEQSELVI, reinforcing its position in the U.S. market. The company’s next steps will be closely watched as it transitions from litigation to commercial execution.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Coromandel International Ltd has signed a Memorandum of Understanding (MoU) with Saudi Arabia’s Ma’aden for the long-term supply of Di-Ammonium Phosphate (DAP) and NP/NPK fertilisers. As per the reports, the agreement was signed on April 9 and builds on a long-standing relationship between the two companies.

As of 9:39 AM on April 11, 2025, Coromandel International share price was trading at ₹2080, a 3.76% up, it has gained 23.31% over the past six months and 74.94% over the past year.

Background

Ma’aden has been supplying ammonia to Coromandel for several years. It has also been India’s largest supplier of phosphate fertilisers for over a decade. The new MoU is to support the regular availability of fertilisers in India, which has recently seen supply disruptions.

Ma’aden’s Expansion 

To meet growing demand, Ma’aden is increasing its phosphate fertiliser production from 6 million tonnes to 9 million tonnes. In 2024, the company reported revenue of SAR 39.88 billion (approximately USD 10.72 billion).

Coromandel’s Reach

Coromandel is the second-largest manufacturer and marketer of phosphatic fertilisers in India. It operates in two segments: nutrients and crop protection. The company runs 18 manufacturing facilities and over 900 retail outlets across Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu. Through these outlets, it serves more than 4.5 million farmers.

In Q3 FY25, Coromandel’s consolidated net profit rose 121.6% year-on-year to ₹511.77 crore. Net sales stood at ₹6,935.19 crore, up 26.9% from the previous year.

Conclusion

The agreement secures a long-term fertiliser supply to India and signals continued cooperation between the two companies in different areas, including raw material sourcing and agricultural input support.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Waaree Renewable Technologies Ltd (WRTL), a solar EPC (engineering, procurement and construction) company, has been listed on the National Stock Exchange (NSE) as of April 10. The company is now trading under the symbol WRTL.

As of 9:44 AM on April 11, 2025, Waaree Renewable Technologies share price was trading at ₹883.85, a 3.17% up. The listing gives WRTL public market access, expanding its investor base and visibility.

Completed and Ongoing Projects

WRTL has completed over 1.82 gigawatts (GW) of solar EPC installations so far. In addition, the company is currently executing another 1.7 GW worth of solar projects. These include large-scale solar plants across multiple regions.

Future Pipeline

WRTL has a bidding pipeline of 17.8 gigawatt-peak (GWp), which consists of upcoming projects the company is pursuing through tenders. The pipeline showcases both the scale of opportunity in the solar EPC space and the company’s growth ambitions.

Focus on Data Centres

Apart from utility-scale solar projects, the company is also providing solar energy solutions for data centres. As demand for digital infrastructure grows, the energy requirements for such centres are increasing, creating new opportunities for solar providers.

Company’s Statement

In an official statement, the company referred to the NSE debut as a key milestone in its journey. Director Viren C Doshi said that the listing symbolises credibility, scale, and intent. The company also noted that the listing would help improve access to capital and support future growth.

About WRTL

Waaree Renewable Technologies is involved in end-to-end solar project execution. Its services include planning, procurement, and construction for solar infrastructure projects.

Conclusion

The NSE listing comes at a time when WRTL is expanding its project base. With completed projects, ongoing work, and a large bidding pipeline, the company remains active in India’s renewable energy sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

NTPC Green Energy Limited (NGEL), a subsidiary of NTPC Limited, has officially announced the incorporation of a new joint venture company named NTPC-MAHAPREIT Green Energy Limited to develop a massive 10 GW Renewable Energy Parks. This entity, incorporated on 8th April 2025, marks a strategic partnership between NGEL and Mahatma Phule Renewable Energy and Infrastructure Technology Limited (MAHAPREIT). NGEL holds a 74% stake, while MAHAPREIT holds the remaining 26%. The primary objective of this venture is to focus on the development, operation, and maintenance of renewable energy parks and projects across India, especially in Maharashtra.

This initiative is a noteworthy development in India’s clean energy landscape, symbolising collaboration between major public sector undertakings to scale green infrastructure. The incorporation received requisite approvals from key governmental bodies, including the Ministry of Power, DIPAM, and NITI Aayog.

Second Phase of Dayapar Wind Energy Project Commissioned

NTPC Renewable Energy Limited, a fully owned subsidiary of NTPC Green Energy Limited (NGEL), has formally declared the commercial operation of the second phase of its 150 MW Dayapar Wind Energy Project. With this, an additional capacity of 90 MW has been successfully commissioned and became operational from 00:00 hours on 9th April 2025. The project is part of a larger 450 MW Hybrid Project located in Dayapar, Bhuj, Gujarat.

This milestone follows the earlier commissioning of the first 50 MW segment, which was declared commercially operational on 4th November 2023. The achievement highlights NTPC’s ongoing commitment to expanding India’s renewable energy portfolio and strengthening its sustainable power infrastructure.

A Major Boost to India’s Hybrid Energy Infrastructure

The Dayapar Wind Energy Project is a key component of NTPC’s broader strategy to integrate diverse renewable energy sources, particularly under hybrid project structures. The 450 MW Hybrid Project combines both solar and wind resources to ensure efficient and reliable power generation.

By commissioning this second phase of wind capacity, NTPC Green Energy Limited enhances the total operational capacity under the hybrid model, optimising grid stability and contributing towards national renewable energy targets. The successful rollout also reflects the organisation’s technical capabilities and focus on timely execution.

NTPC Green Share Performance 

As of April 09, 2025, at 2:30 PM, NTPC Green share price is trading at ₹95.49 per share, reflecting a decline of 0.96% from the previous day’s closing price

Conclusion

The commercial launch of the 90 MW wind capacity marks a significant achievement for NTPC Renewable Energy Limited and reinforces NTPC Green Energy’s role in India’s transition to sustainable energy. With the full 150 MW now operational at Dayapar, the company continues to play a vital role in driving hybrid renewable solutions across the country.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Concord Biotech Limited, a pharmaceutical company headquartered in Gujarat, India, has achieved a significant milestone with its latest announcement. On April 8, 2025, the company disclosed that it has secured final approval from the United States Food and Drug Administration (USFDA) to market Teriflunomide tablets in 7 mg and 14 mg dosages. This approval marks a pivotal step in the company’s journey towards expanding its presence in international markets, particularly in the high-value pharmaceutical segment of the United States.

The approved drug, Teriflunomide, is used in the treatment of relapsing forms of multiple sclerosis (MS), a chronic illness that affects the central nervous system. The development of this product underscores Concord Biotech’s growing capabilities in formulating and delivering differentiated therapeutic solutions on a global scale.

Strategic Relevance of the Approval 

Securing USFDA approval is widely regarded as a hallmark of pharmaceutical excellence and regulatory compliance. For Concord Biotech, this approval is more than just an entry into a new market—it is a testament to the company’s research and development strength. The U.S. market, being one of the largest and most regulated in the world, opens up considerable commercial opportunities for the company.

According to data from IQVIA™, the U.S. market for Teriflunomide tablets stands at approximately $402 million, while the global market is valued at around $908 million. By entering this segment, Concord not only strengthens its international footprint but also positions itself as a competitive player in the neurological disorders segment, a space increasingly characterised by innovation and high demand.

Expanding Global Outlook

The approval aligns with Concord Biotech’s long-term strategy of diversifying its product offerings and entering regulated markets with high growth potential. The company has consistently focused on differentiated products that can address unmet medical needs. By obtaining clearance to commercialise Teriflunomide in the U.S., Concord is demonstrating its commitment to expanding its reach and making critical therapies accessible across borders.

Moreover, the commercialisation of Teriflunomide tablets adds to Concord’s growing portfolio of approved products, bolstering its reputation as a reliable supplier of niche and essential pharmaceuticals. This achievement not only strengthens the company’s credibility among global stakeholders but also enhances its ability to contribute meaningfully to the treatment of neurological conditions worldwide.

Concord BioTech Share Performance 

As of April 09, 2025, at 2:30 PM, Concord Biotech share price is trading at 1,607.95 per share, reflecting a surge of over 0.71% from the previous day’s closing price.

Conclusion

Concord Biotech’s latest regulatory milestone represents a strategic victory in its ongoing mission to deliver cutting-edge therapies to global markets. The USFDA’s approval of Teriflunomide tablets highlights the company’s robust R&D efforts and its potential to tap into substantial market opportunities in both the United States and worldwide. With a strong pipeline and clear global ambitions, Concord is well-positioned to make a lasting impact in the pharmaceutical sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing